Based in Melbourne, Cipla Australia has a vast pipeline of products that are supplied in Australia as well as US & EU. Millions of Australians have access to a Cipla manufactured product through our community pharmacy partners around Australia.

Quick Explore

Our state-of-the-art manufacturing facilities are TGA approved as well as being USFDA (USA) and MHRA (UK) approved. Cipla Australia has over 200 registered?formulations?with TGA through partnerships with market leaders and on its own. The list of registered medicines includes OTC (Over the Counter), Prescription and hospital medicines. We are also involved in helping Australians access medicines through the SAS (Special Access Scheme). Cipla has earned a name for maintaining world-class quality across all our manufacturing units, products and services. Globally, our patent filing includes drug substances, drug products, platform technologies, IP on polymorphs and crystallinity, and medical devices.

Registered Office
Cipla Australia Pvt. Ltd,?
Level 1, 132 Albert Road,
South Melbourne, Vic 3205

Leadership in Respiratory

Cipla has a long heritage of being a world leader in Respiratory Therapy - India, South Africa and various Emerging Markets to name a few. In keeping with our purpose of ‘Caring for Life’, we are constantly working towards improving patient access to necessary and innovative medicines for better management of diseases and improved quality of life. We pride ourselves in having the world’s largest respiratory range of drugs, dosage forms and devices for COPD and Asthma. Our products are available in more than 80+ countries worldwide. Key products were successfully launched in many European countries e.g. UK, Germany, Belgium, Netherlands, Czech Republic and Croatia.

Pioneers in Respiratory

1996 - Transparent Rotahaler

The world’s first transparent dry powder inhaler - the simplicity and ease of use thereafter changed the face of inhalation therapy in India

2003-Tiova pMDI

The world’s first tiotropium bromide pressurized Metered Dose Inhaler (pMDI), launched in India for the long term management of Chronic Obstructive Pulmonary Disease (COPD).

2004 - Duonase

The world’s first combination of an antihistamine and a steroid in a nasal spray for comprehensive treatment of allergic rhinitis


The world’s first combination of two long-acting Bronchodilators – Tiotropium Bromide and Formoterol – for the treatment of COPD


The world’s first 3-in-1 combination inhaler for the treatment of COPD

2008 - Zerostat VT

World’s first transparent anti-static spacer with a unidirectional valve

2017 – Synchrobreath

A unique breath actuated inhaler

Our Products

Salmeterol + Fluticasone Cipla

Active Ingredients

Fluticasone propionate and salmeterol xinafoate.


Consumer Medicine Information is a document that has information about the product for people who were prescribed the medicine. Patients are advised to discuss the content of this document as well as any concerns with their health professional. It only applies to Australia.


Product Information is a leaflet that is intended to assist health professionals with product information. It shall only be used for the Australian product.

Download CMI | Download PI